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Background: Myofibrillar myopathies (MFM) are a group of phenotypically and genetically heterogeneous
neuromuscular disorders, which are characterized by protein aggregations in muscle fibres and can be associated
with multisystemic involvement.
Methods: We screened a large cohort of 38 index patients with MFM for mutations in the nine thus far known
causative genes using Sanger and next generation sequencing (NGS). We studied the clinical and histopathological
characteristics in 38 index patients and five additional relatives (n = 43) and particularly focused on the associated
multisystemic symptoms.
Results: We identified 14 heterozygous mutations (diagnostic yield of 37%), among them the novel p.Pro209Gln
mutation in the BAG3 gene, which was associated with onset in adulthood, a mild phenotype and an axonal
sensorimotor polyneuropathy, in the absence of giant axons at the nerve biopsy. We revealed several novel clinical
phenotypes and unusual multisystemic presentations with previously described mutations: hearing impairment with
a FLNC mutation, dysphonia with a mutation in DES and the first patient with a FLNC mutation presenting
respiratory insufficiency as the initial symptom. Moreover, we described for the first time respiratory insufficiency
occurring in a patient with the p.Gly154Ser mutation in CRYAB. Interestingly, we detected a polyneuropathy in 28%
of the MFM patients, including a BAG3 and a MYOT case, and hearing impairment in 13%, including one patient
with a FLNC mutation and two with mutations in the DES gene. In four index patients with a mutation in one of
the MFM genes, typical histological findings were only identified at the ultrastructural level (29%).
Conclusions: We conclude that extraskeletal symptoms frequently occur in MFM, particularly cardiac and
respiratory involvement, polyneuropathy and/or deafness. BAG3 mutations should be considered even in cases with
a mild phenotype or an adult onset. We identified a genetic defect in one of the known genes in less than half of
the MFM patients, indicating that more causative genes are still to be found. Next generation sequencing
techniques should be helpful in achieving this aim.
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Myofibrillar myopathies (MFM) are a group of pheno-
typically and genetically heterogeneous neuromuscular
disorders. The morphological hallmark of MFM is the
presence of protein aggregations in muscle fibres, a focal
myofibrillar disorganisation starting at the Z-disk and an
ectopic expression of proteins, such as desmin [1-6].
Muscle biopsies of MFM patients reveal protein aggre-
gates that are dark blue or purple on the modified Gomori
trichrome (mGT) and pink on the haematoxylin and eosin
(HE) stains. The aggregations are lacking oxidative enzyme
activity on the nicotinamide adenine dinucleotide tetra-
zolium reductase (NADH-TR) stains. Other light micro-
scopic findings in MFM are rimmed and non-rimmed
vacuoles and sometimes cytoplasmic bodies. At the ul-
trastructural level, the combination of Z-disk streaming
and distinct types of protein accumulations is charac-
teristic for MFM and can even give hints towards the
mutated gene [7].
To date, mutations in nine genes are known to cause
MFM: desmin (DES) [8], αB-crystallin (CRYAB) [9],
myotilin (MYOT, also TTID) [10], filamin C (FLNC)
[11], Z-band alternatively spliced PDZ motif-containing
protein (ZASP, also LDB3) [12], four and a half LIM do-
main protein 1 (FHL1) [13], bcl-2 associated athanogene
protein 3 (BAG3) [14], dnaJ homolog subfamily B mem-
ber 6 (DNAJB6) [15] and titin (TTN) [16]. Mutations in
exon 343 of the A-band region of TTN were discovered
to cause MFM only very recently [16]. Inheritance in
MFM is autosomal dominant in most patients, auto-
somal recessive in rare cases and X-linked in patients
with mutations in FHL1. A broad inter- and intrafami-
lial variability of phenotypes can be seen in MFM. The
age at onset of MFM depends on the underlying gene,
mutation and inheritance pattern, but usually the
disease starts in adulthood [17,18]. Nevertheless also
childhood onsets have been described [8,13,14,19-21].
The initial symptom in MFM most frequently is skeletal
muscle weakness, other muscular symptoms such as
atrophy, hypertrophy, muscle rigidity, contractures, pain
or cramps can be present [13,22-26]. Also, the respiratory
muscles can be affected in MFM, resulting in a restrictive
respiratory insufficiency, which has been reported for
most MFM subtypes [4,8,11,14,27-31].
Furthermore, MFM can be associated with distinct
multisystemic symptoms, the most frequent being
cardiac involvement, ranging from conduction defects and
arrhythmias to cardiomyopathies and sudden cardiac death
[4,9,15,26,29,30,32-38]. The smooth muscles can also be
affected in MFM, presenting as chronic diarrhoea or enteric
hypomotility [37,39-42], or contributing to bulbar symp-
toms like swallowing difficulties [27,28,31,33,37,43-45].
Further symptoms associated with MFM exceed the
muscles, such as polyneuropathy (PNP) [10-12,14,46],cataracts [9,31,33], gynaecomastia [29,47], and hearing
impairment [39,40,48,49].
Serum creatine kinase levels (CK) in MFM patients
are normal or only slightly elevated. Electromyography
(EMG) reveals myopathic or mixed patterns, but also
(pseudo-) myotonic discharges can appear [17,50]. Mag-
netic resonance imaging (MRI) of the muscles plays an
increasing role in the differential diagnosis of muscular
disorders and of MFM in particular [51,52].
In the present study, we screened a large cohort of 38
unrelated index patients with MFM for mutations in the
nine causative genes, employing next generation sequen-
cing (NGS) and traditional Sanger sequencing. We iden-
tified a mutation in 14 index patients, including one
novel BAG3 mutation. We performed a detailed clinico-
pathological characterisation in the index patients and
five affected relatives and particularly focused on the asso-
ciated multisystemic symptoms. We highlight new pheno-
typical findings in MFM and correlate our data with the
literature.Patients and methods
Patients
In this study, we included 43 patients with MFM belong-
ing to 38 unrelated families (Figure 1). We selected the
MFM cases from the muscle and nerve biopsy archive at
the Institute of Neuropathology, and from the Neuro-
muscular Clinic at the Department of Neurology, at the
RWTH Aachen University Hospital (Aachen, Germany).
The biopsy of patient F10.1 was also included in the study
of Joshi et al. [53]. Additionally, eight index patients/
biopsies with MFM were provided by referring centres.
The study was performed according to the Declaration
of Helsinki and was approved by the ethical committee
of the RWTH Aachen University. Written informed
consent was obtained from all patients.Clinical and paraclinical evaluation
In all 43 patients, we performed a detailed neurological
examination, including hearing and swallowing tests,
and a blood analysis of the creatine kinase (CK) level.
Nerve conduction velocity (NCV) and electromyography
(EMG) studies, heart (electrocardiogram (ECG), echo-
cardiography, long-term ECG) and lung examinations
(spirometry/bodyplethysmography) were performed in
the majority of patients. In addition, an ophthalmological
exam was undertaken in patients with complaints of ocu-
lar involvement. An EMG was done in all patients with an
identified gene defect, except for patients F5.II.2 and
F14.1, a diagnostic muscle MRI of the lower extremities
in four patients (F1.III.1, F2.III.4, F10.1, F12.III.3) and a
whole-body muscle MRI in one (F7.III.4) (1.5 Tesla,
Philips, Intera, Best – the Netherlands).
Figure 1 Pedigrees of MFM patients with a confirmed mutation and autosomal dominant inheritance. Index patients are indicated by an
arrow; m|n, mutated allele| wildtype allele, indicating all patients who are genetically confirmed heterozygous mutation carriers.
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muscle and nerve biopsies
Open muscle biopsies had been obtained from the 38
index patients for diagnostic purposes after written
informed consent. The muscle tissue sample was divided
into unfixed (cryostat), formaldehyde-fixed (paraffin)
and glutaraldehyde-fixed (EM) sections and further pre-
pared according to routine protocols. Standard enzyme
histochemical and immunohistochemical stains were
applied [54]. For electron microscopy (EM) of muscle
tissue, which was performed in 31 out of 38 probands,
we used a CM10 transmission electron microscope
(Philips, Amsterdam, the Netherlands). In addition,
seven index patients had simultaneously a diagnostic
sural nerve biopsy taken, among them patient F9.1 and
F13.1 with a confirmed mutation and a polyneuropathy.
The nerve biopsies were processed following standard
procedures [55].
Genetic analyses
Peripheral blood samples and a written informed con-
sent for genetic analysis were available from the 38 index
patients, as well as from the affected mother of patient
F7.IV.2, the affected brother of patient F5.II.2, the cousin
of patient F12.III.4 and the son of patient F14.1. Genomic
DNA was extracted using standard procedures. We
used two different techniques for genetic analyses in
our cohort: Sanger sequencing [56] and next generation
sequencing (NGS) [57].
Sanger sequencing of the MFM genes
We had started screening a group of 21 MFM index
patients with conventional Sanger sequencing before
the NGS panel for MFM was established. We analysed
DES, CRYAB, MYOT (exon 2 and 9), FLNC (exon 48),
ZASP (exon 4–10), FHL1, BAG3 and DNAJB6. We
performed PCR using standard protocols and used the
BigDye Terminator v1.1 mix (Applied Biosystems) for
cycle sequencing reactions according to the instruc-
tions in the kit. Sequence data were generated with an
ABI 3130xl capillary sequencer (Applied Biosystems,
Carlsbad, CA, USA) using standard protocols and ana-
lysed by GenSearch v.4.0.8 (PhenoSystems, Lillois,
Belgium).
NGS panel diagnostics in MFM
In a NGS approach, the coding exons of all causative
genes with the exception of the most recently identified
TTN gene were sequenced in the additional 17 index
patients included in our study: DES (exon 1–9, NM_
001927.3), MYOT (exon 2–10, NM_006790.2), ZASP
(exons 5–9 of NM_001080116.1 and exons 4, 7, 8 and 10
of NM_007078.2), FHL1 (exon 3–8, NM_001159702.2),
BAG3 (exon 1–4, NM_004281.3), DNAJB6 (exon 2–8,NM_005494.2), CRYAB (exon 1–3, NM_001885.1) and
FLNC (exon 1–48, NM_001458.3). Furthermore, in 10
index patients of our first cohort in which Sanger sequen-
cing was initially performed (see above) and in which no
mutations were identified, we subsequently analysed the
complete FLNC gene (exon 1–48) applying NGS. Target
enrichment was performed with the Access Array Sys-
tem (Fluidigm Corporation, South San Francisco, USA)
followed by emulsion PCR and sequence analyses on a
GS Junior using kits and instructions by Fluidigm and
454 Life Sciences (Branford, USA). Sequence data were
analysed with GenSearch NGS v.1.4 (PhenoSystems,
Lillois, Belgium) automatically aligning data to the
reference sequences mentioned above. Variants within
exons and 20 bp of the flanking intronic sequences were
detected with VarScan (http://varscan.sourceforge.net/)
using following filters: coverage >15, frequency >20%
for heterozygous or >75% for homo- and hemizygous
variants. Candidate variants were verified by Sanger se-
quencing on an ABI 3130xl automated capillary sequen-
cer using standard protocols, and their effect predicted
with bioinformatic tools like PolyPhen-2 (http://genetics.
bwh.harvard.edu/pph2/index.shtml), SIFT (http://sift.jcvi.
org/) and MutationTaster (http://www.mutationtaster.org/)
provided by Alamut (Interactive Biosoftware, Rouen,
France).
Sanger sequencing of exon 343 of TTN
Finally, we performed Sanger sequencing to analyse exon
343 of TTN in 25 of our index patients, in whom an
underlying gene defect had thus far not been identified
(21 patients) or only an unknown variant was revealed
(4 patients). PCR, sequencing reaction and data analysis
of exon 343 of the TTN gene (NM 001267550.1) have
been performed using standard protocols as described
above.
Results
Genetic results in our MFM cohort (n = 43): known and
novel pathogenic mutations
In 14 index patients, we identified a heterozygous patho-
genic mutation in one of the nine genes causing MFM
(Table 1), corresponding to a diagnostic yield of 37% in
our MFM cohort. In ten patients we found the under-
lying gene defect using the initial Sanger sequencing
study and in four patients by directly employing NGS
panel diagnostics. Nine out of the 14 index patients had
a positive family history corresponding with an auto-
somal dominant inheritance (for pedigrees see Figure 1),
whereas the others occurred sporadically (Patient F6.1
with a DES mutation, Patient F13.1 with a mutation in
BAG3 and all three patients, F9.1, F10.1 and F11.1, with
a MYOT mutation, Table 1). We identified six heterozy-
gous mutations in DES, four of these were the Arg350Pro
Table 1 Clinical characteristics of myofibrillar myopathy patients with an identified mutation
Pat. M/F FH Gene Exon Mutation AAO AAE First
symptom
Weakness Multisystemic symptoms CK
UL
prox.
UL
dist.
LL
prox.
LL
dist.
ptosis axial scapular
winging
dys-
phagia
dys-
phonia
respiratory
involvement
cardiac
involvement
PNP hearing
imp.
F1.III.1 M + DES 6 Arg350Pro 39 47 weakness LL + - + + - - - - - - - - - 1031
F2.III.4 M + DES 6 Arg350Pro 42 74 weakness LL - - + + - + - - - - - - - 2690
F3.II.3 M + DES 6 Arg350Pro 48 59 dyspnoea + + + + + - - - - VC 45%,NV TAA intermittent,
LV hypertrophy
- + 2044
F4.II.2 M + DES 6 Arg350Pro 36 42 weakness LL + - + + - - - + - - - - + 1159
F5.II.2 M + DES 1 Ser2Ile 60 72 syncopes + - + + - + + - - - 3°AVB, PM - - nl
F6.1 F - DES 3 Glu245Asp 51 62 weakness LL - - + + - - - - - - DCM, AF, 3 °AVB,
PM, TI
- - nl
F7.IV.2 M + FLNC 18 Val930_Thr
933del
28 40 weakness LL - - + - - - + - - - - - - 629
F7.III.4 F + FLNC 18 Val930_Thr
933del
53 60 weakness LL - - + + - - - - - - - - + 388
F8.III.3 F + FLNC 48 Trp2710X 53 59 dyspnoea + - + + - - + - - VC 35%,NV - - - 500
F9.1 M - MYOT 2 Ser60Phe 67 71 dyspnoea - - - + + - - - - - LBBB, HF, AF,
3°AVB intermittent,
PM
ad/sm - 206
F10.1 M - MYOT 2 Ser60Phe 63 67 myalgia LL - - + - - - - - - - - - - 589
F11.1 M - MYOT 2 Ser55Phe 55 60 weakness LL + - + + - - - - - mild AF, PM, ICD, DCM,
HTx,
- - 608
F12.III.3 F + ZASP 6 Ala165Val 46 57 walking
difficulties
- + - - - - - - - - - - - 182
F13.1 M - BAG3 3 Pro209Gln 34 43 weakness LL + - + + - - + - - - - a/sm - 1050
F14.1 M + CRYAB 3 Gly154Ser 69 69 rhabdomyolysis - - - - - - - - - VC 65% - - - 2000
M/F, male/female; FH, family history; AAO, age at onset; AAE, age at examination; CK, level of creatine kinase in serum in U/L (normal value < 174); UL, upper limb; LL, lower limb; prox., proximal; dist., distal; PNP,
polyneuropathy; Hearing imp., hearing impairment; VC, vital capacity; NC, nocturnal ventilation; TAA, tachyarrhythmia absoluta; LV, left ventricle; 3° AVB, complete atrioventricular conduction block; nl, normal; DCM,
dilated cardiomyopathy; AF, atrial fibrillation; PM, pace maker; TI, tricuspid insufficiency; LBBB, left bundle branch block; HF, heart failure; ad/sm, axonal demyelinating/sensorimotor; ICD, implantable cardioverter
defibrillator; HTx, heart transplantation; a/sm, axonal/sensorimotor; for abbreviations of genes see text.
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MYOT mutations, including two times the Ser60Phe mu-
tation in exon 2. One mutation each was found in ZASP,
CRYAB and in BAG3 (Table 1, Figure 1). The mutation in
BAG3 represents a novel mutation, whereas the other
mutations have been described previously.
The c.626C > A, p.Pro209Gln mutation in exon 3 of
BAG3 (Patient F13.1, Table 1) is so far not known in the
databases of the NHLBI exome sequencing project (ESP)
or the 1000 genome project and was predicted to be dis-
ease causing by all used prediction programmes. Further
arguments for pathogenicity came from familial segrega-
tion analysis, in which both healthy parents did not
harbour the mutation, indicating a de novo mutation.
Genetic results in our MFM cohort (n = 43):
polymorphisms and unclassified variants
With means of NGS panel diagnostics we found a large
number of variants, especially in FLNC. The suspicious
variants with a minor allele frequency beneath 1% are
listed in Additional file 1. We assessed these variants
with various databases and prediction programmes. Espe-
cially the pathogenicity of the c.6595G >A, p.Gly2199Arg
mutation in exon 40 of FLNC (patient F20.1, Additional
file 1) finally remained unclear. This genetic variant has
only been counted once by the NHLBI exome sequen-
cing project (ESP) and was predicted to be benign by
PolyPhen-2, but disease causing by Mutation Taster.
The glycin residue at position c.6595 is highly con-
served, as well as the nucleotide at this position. Unfixed
muscle tissue of this patient was not available anymore
and no new muscle biopsy could be obtained, so that add-
itional proteomic analyses for possible further clarification
could not be performed. Moreover, family members were
not available for segregation analysis to further clarify the
pathogenicity.
Clinical findings in MFM patients with an identified gene
defect (n = 14)
The 14 index patients with an identified mutation in-
cluded eleven males and three females (Table 1). The age
at onset ranged from 28 to 69 years (mean 49 years). The
most common initial symptom was weakness in the legs
(64%). In three patients the first symptom was dyspnoea
(21%) and in one syncopes (7%), indicating a respiratory
or cardiac onset of the disease. At the time of examination,
the disease persisted already up to 32 years (mean disease
duration 9 years). Muscle weakness was distributed in the
distal and proximal lower limbs, combined with weakness
in the proximal upper limbs in six of the 14 patients.
Patients F3.II.3 and F6.1 were wheelchair bound since
the age of 59 and 60 years respectively, both after
11 years of disease progression. Scapular winging was
evident in 29% of the patients, 14% showed additionalaxial weakness and 14% a ptosis without ophthalmo-
paresis or facial weakness (Table 1). In 64% of the
patients, atrophy of the distal lower limbs was present,
among them the two patients with an additional PNP.
EMG revealed a myopathic pattern in 58% and a mixed
pattern in 42%, in three of the patients with a mixed
pattern also pseudomyotonic discharges were present.
The serum CK levels varied from normal to 16 fold
elevated (mean: 5.5 N) (Table 1). Only patient F14.1 did
not show permanent skeletal muscle weakness.
Multisystemic symptoms in the whole MFM cohort
(n = 43)
In general, 16% of the patients included in the study
(n = 43) had respiratory involvement and 60% presented
one or more multisystemic symptom(s) (Table 2). The
most striking finding was the large number of MFM
patients with mainly a sensorimotor axonal-demyelinating
polyneuropathy (12/43 or 28%), which occurred as fre-
quently as cardiac disease (Table 2). In 50% (n = 6) of the
MFM patients with a polyneuropathy, no other possible
cause was present. However, another 33% (n = 4) suffered
from diabetes mellitus and 17% (n = 2) had taken neuro-
toxic medications, as possible (additional) causes of a
polyneuropathy. The PNP was diagnosed after 0–6 years
of disease duration (mean: 1.7 years). 14% of the MFM
patients suffered from hearing impairment, with a symp-
tom onset between 16 and 80 years of age. Half of these
patients used hearing devices. We did not detect diar-
rhoea, intestinal malabsorption or pseudoobstruction in
our cohort.
Multisystemic symptoms in MFM patients with an
identified mutation (n = 14 and affected relatives)
In the group of index patients with a pathogenic muta-
tion (n = 14) 64% showed at least one multisystemic
symptom (Figure 1, Tables 1 and 2). Patient F3.II.3 har-
bours the Arg350Pro mutation in DES and presented
with exertional dyspnoea as initial symptom at 48 years
of age. Subsequently, he developed dyspnoea at rest, had
a vital capacity (VC) of 45% of the theoretical value and
needed non-invasive continuous positive airway pressure
(CPAP) ventilation at night. Furthermore, he presented
an intermittent tachyarrhythmia absoluta and a hyper-
trophic left ventricle at echocardiography. He also suffered
from bilateral hypacusis and used a hearing aid on the
right side since the age of 52 years.
Patient F4.II.2 carried the same Arg350Pro mutation
in DES and recognised swallowing problems after six years
of disease progression. He also presented a bilateral hypa-
cusis since the age of 38 years.
Only the affected mothers of two more patients with
the Arg350Pro mutation in DES (patient F1.III.1; F2.III.4)
showed multisystemic symptoms (respiratory insufficiency,
Table 2 Multisystemic symptoms of all included MFM patients (n = 43)
Symptom Frequency
Respiratory symptoms (6) restricted vital capacity 6** (1x DES, 1x FLNC, 1x MYOT, 1x CRYAB)
ventilation assistance 1
nocturnal ventilation 2 (1x DES, 1x FLNC)
Cardiac symptoms (12) atrial fibrillation 8 (1x DES, 2x MYOT)
tachyarrhythmia absoluta 1 (1x DES)
ventricular tachycardia 1
bradycardia 1
ventricular extrasystoles 1
3° AV block 3* (2x DES, 1x MYOT)
LBBB 2 (1x MYOT)
RBBB 1
bifascicular block 1
tricuspid insufficiency 2 (1x DES)
aortic/mitral/tricuspid insufficiency 1
heart failure 3 (1x MYOT)
LV hypertrophy 3
DCM 2 (1x DES, 1x MYOT)
pace maker 6 (2x DES, 2xMYOT)
ICD 1 (1x MYOT)
heart transplantation 1 (1x MYOT)
sudden cardiac death 0
Polyneuropathy (12) axonal 3 (1x BAG3)
demyelinating 0
axonal-demyelinating 9 (1x MYOT)
sensory 0
sensory + autonomic 1
motor 1
sensorimotor 10 (1x MYOT, 1x BAG3)
Bulbar symptoms (8) dysphagia 5 (1x DES)
dysphonia 2 (1x DES)
Hearing impairment 6 (2x DES, 1x FLNC)
Gynaecomastia 1
One patient can present more than one multisystemic symptom; between brackets, the number of cases with an identified mutation in whom the symptom was
present; **, symptom was the onset symptom in two cases; 3° AV block, complete atrioventricular conduction block; *, symptom was the onset symptom in one
case; LBBB, left bundle branch block; RBBB, right bundle branch block; LV, left ventricle; DCM, dilated cardiomyopathy; ICD, implantable cardioverter defibrillator.
Semmler et al. Orphanet Journal of Rare Diseases 2014, 9:121 Page 7 of 13
http://www.ojrd.com/content/9/1/121cardiac involvement with a pace maker implantation,
polyneuropathy).
Patient F6.1 carried the Glu245Asp mutation in DES
and exhibited cardiac symptoms: a dilated cardiomyop-
athy was diagnosed approximately ten years after dis-
ease onset and a chronic atrial fibrillation and complete
atrioventricular block occurred, necessitating pace maker
implantation.
The patient carrying the Ser2Ile mutation in DES
(patient F5.II.2) presented with syncopes as the first
symptom at the age of 60 years, due to a completeatrioventricular conduction block leading to pace maker
implantation. At the age of 65 years, he developed mild
distal lower leg weakness and dysphonia. Other causes of
dysphonia were excluded. Interestingly, the patient’s father
also had dysphonia and a pacemaker implantation at the
age of 58 years. The patient’s brother, carrying the same
mutation, received a pacemaker at the age of 45 years
and had mild distal involvement of the lower legs, but
no dysphonia.
Patient F8.III.3 with the Trp2710X mutation in FLNC
developed respiratory problems three years before
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disease progression, the patient was dependent on non-
invasive nocturnal ventilation. VC decreased to 35%.
The affected mother of the index patient harbouring
the Val930_Thr933del mutation in FLNC (patient F7.III.4)
presented with bilateral hearing impairment and hearing
aids at the age of 60 years.
Patient F9.1 carrying the Ser60Phe mutation in MYOT
developed exertional dyspnoea due to heart failure at the
age of 64 years as the first symptom. A left bundle
branch block, an intermittent atrioventricular conduc-
tion block and atrial fibrillation were diagnosed, and a
pace maker was implanted. The patient also suffered
from coronary disease. Four years later, a sensorimotor
axonal-demyelinating polyneuropathy was diagnosed.
In Patient F11.1 with a Ser55Phe mutation in MYOT,
cardiac symptoms began shortly after skeletal weakness
became apparent at the age of 55 years. He had a perman-
ent atrial fibrillation with tachyarrhythmia absoluta and
received an implantable cardioverter defibrillator (ICD).
In addition, he had several myocardial infarctions dueTable 3 MRI findings in five MFM patients with an identified
Fischer et al. 2008
Gene DES FLNC MYOT ZASP*
Patient
Pelvic level
Gluteus maximus 2,3 1,3 2 3
Gluteus medius 1,8 1,7 2,8 1
Gluteus minimus 1,8 1,7 3,3 3
Mid thigh level
Vastus lateralis 1,2 1,2 1,6 2
Vastus intermedius 1,2 2,8 2,8 3
Vastus medialis 1,3 2,3 2,8 3
Rectus femoris 1,3 0,4 0,1 2
Sartorius 2,8 0,7 1,5 1
Gracilis 2,2 0,6 0,4 1
Biceps femoris 1,5 3,3 2,9 4
Adductor magnus 1,7 3,2 3,2 4
Semitendinosus 3,1 1,8 1,2 3
Semimembranosus 1,5 3,3 2,8 4
Mid leg level
Tibialis anterior 1,9 2,8 3,1 3
Peroneal muscle group 3 2,7 2,8 3
Medial gastrocnemius 2 3 3,4 3
Lateral gastrocnemius 2,1 0,9 2,1 3
Soleus 2,2 3,6 3,9 4
5-point scale according to Fischer et al. 2008 [51]: stage 0 is referred to a normal m
T1-weighted MR sequences; stage 2 refers to increased signal intensity on MRI in le
in more than 50% of the muscle; stage 4 indicates an increased signal intensity on
Figure four in the study of Fischer et al. 2008; np, not performed; for abbreviationsto coronary disease. One year later, a dilated cardiomy-
opathy was diagnosed and heart transplantation was
performed.
Patient F14.1 carries the p.Gly154Ser mutation in
CRYAB and presented at the age of 69 years with several
episodes of rhabdomyolysis. The patient also complained
about exercise intolerance and fatigue. The neurological
examination was normal, but a respiratory involvement
with a VC of 65% in lying position was diagnosed. His
42-year-old son, carrying the same mutation, was asymp-
tomatic and only showed a moderate serum CK elevation.
MRI findings in MFM patients with an identified mutation
Muscle MRI findings are summarised and compared to
the literature in Table 3.
Histological findings of the MFM cohort
In the 14 index patients with an identified mutation we
consistently found an increased variability of fibre diam-
eter (100%), frequent nuclear bags (64%), internal nuclei
(86%), vacuoles (64%), rimmed vacuoles (50%) andmutation
Current study
DES FLNC MYOT ZASP
F1.III.1 F2.III.4 F7.III.4 F10.1 F12.III.3
3 np 1 np np
1 np 1 np np
3 np 1 np np
3 1 2 1 1
4 1 3 1 1
4 1 3 1 1
1 1 2 1 1
4 3 1 2 1
3 3 1 1 1
1 1 3 3 3
3 1 3 3 2
3 3 3 2 1
2 1 3 2 3
3 2 0 1 3
2 4 1 1 2
2 3 3 4 4
2 3 1 3 4
4 2 3 3 4
uscle appearance; stage 1 means traces of increased signal intensity on the
ss than 50% of the muscle; stage 3 means an increased signal intensity on MRI
MRI in the entire muscle (end-stage disease); *, ZASP classification is based on
of genes see text.
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the biopsies, cytoplasmic bodies and core-like lesions
on the NADH-TR staining were revealed. Myofibrillar
disorganisation was seen in all cases, but characteristic
protein aggregations in the cytoplasm of mGT stained
fibres were found in only 10 of the 14 cases (71%) (Patient
F11.1: in the vastus medialis muscle biopsy protein aggre-
gations were seen, but not in the simultaneously obtained
tibialis anterior muscle biopsy). So 29% only showed
typical MFM findings at the ultrastructural level (EM
was performed in 11 of the 14 cases). Z-disk streaming
and myofibrillar disorganisation were seen in 100%,
granulofilamentous material in 64%. Abnormal mito-
chondria (64%), tubulofilamentous accumulations (29%)
and cytoplasmic bodies (36%) were other frequent
findings. Immunhistochemistry with antibodies directed
against desmin showed immunoreactivity in all 8 per-
formed cases.
In the group of 24 patients, in whom the underlying
genetic defect had not been identified, we made similar
observations. Characteristic protein aggregations in the
cytoplasm of mGT stained fibres were found in 76% of
the cases, myofibrillar disorganisation in 82%.
In ten of the 12 MFM patients additionally presenting
a polyneuropathy, we observed neurogenic muscle atro-
phy, which found expression in angular shaped muscle
fibres and fibre type grouping.Clinicopathological phenotype of the patient with a novel
BAG3 mutation
Patient F13.1 harbours the novel Pro209Gln mutation in
BAG3 (Table 1). He presented first symptoms of distal
lower limb weakness and symmetrical calve atrophy at
the age of 34 years. The skeletal muscle weakness spread
to the proximal lower limbs and finally to the proximal
upper limbs with scapular winging after 2 more years of
disease progression. Moreover, he developed an axonal
sensorimotor polyneuropathy, as multisystemic symptom
of MFM. No other obvious cause for the PNP could be
found. The PNP was first diagnosed at the age of 39 years
and finds expression in decreased vibration sense and
ataxic, clumsy gait as well as an increased sensitivity for
cold. EMG showed a mixed pattern and the maximum CK
level was 1050 U/L (Table 1). The muscle biopsy showed
desmin positive protein deposits, vacuoles and core-like
lesions as well as some necrotic fibres. At the ultrastruc-
tural level, tubulofilamentous accumulations, lobulated
nuclei and glycogen accumulations were seen, in
addition to typical MFM findings like Z-disk streaming
and the accumulation of granulofilamentous material.
We did not observe regenerating fibres or apoptotic
nuclei. The ultrastructural study of nerve tissue revealed
no giant axons.Discussion
In a large cohort of MFM patients, we identified hetero-
zygous mutations in 14 of 38 index patients (diagnostic
yield of 37%), including the novel p.Pro209Gln mutation
in exon 3 of BAG3, using Sanger and next generation
sequencing (NGS) of the nine thus far known causative
genes of MFM. Furthermore, we discovered new pheno-
types associated with previously described mutations,
such as hearing impairment with a FLNC mutation, dys-
phonia with a mutation in DES and the first patient with a
FLNC mutation presenting respiratory insufficiency as the
onset symptom. Interestingly, we detected a polyneurop-
athy in more than a quarter of the MFM patients, includ-
ing a BAG3 and aMYOT case (Figure 2).
Methodological issue: Sanger versus NGS sequencing
In ten of our patients, a mutation in one of the MFM-
causative genes was identified using conventional Sanger
sequencing. By employing NGS, we additionally found
four mutations, among them the novel BAG3 mutation,
as well as a lot of variants, especially in FLNC, beyond
the mutational hotspot in exon 48. The mass of variants
that are found using NGS and their sometimes difficult
interpretation can currently still be considered as a draw-
back of this technique. However, knowledge concerning
the variants will increase in the following years as NGS
will become more widely available and databases more
complete. Advantages of NGS are reduced costs and
decreased time to diagnosis. Furthermore, a specific
and often unreliable genetic testing sequence is made
redundant, especially in diseases with overlapping mor-
phological and/or clinical phenotypes, such as MFM.
The difficulty in interpretation of certain variants is
illustrated by the unknown variant p.Gly2199Arg in
exon 40 of FLNC of patient F20.1 (Additional file 1).
Novel mutation identified in BAG3 and associated
phenotype
The novel BAG3 mutation is located at the amino acid
position p.209 and proline is replaced by glutamine. At
the same position the p.Pro209Leu mutation is situated,
which is the most common BAG3 mutation associated
with MFM [14,36,46,48]. In all previously described MFM
cases with the p.Pro209Leu mutation, the disease started
within the first or second decade and was hallmarked by
rapidly progressive muscle weakness, severe cardiac and
respiratory involvement and early death of the patients in
some cases. In nine of the eleven reported cases an axonal
polyneuropathy was additionally found. Our patient’s
(Patient F13.1, Table 1) mild phenotype with adult-
onset skeletal muscle weakness and the absence of car-
diac or respiratory involvement clearly differs from the
other BAG3-associated MFM cases, solely his axonal
sensorimotor PNP is in concordance. Only one other
Figure 2 Flowchart of multisystemic symptoms of MFM. Underlined, findings in current study; bold, new findings in current study; *, for the
first time described as onset symptom with FLNC mutation in current study; **, for the first time described as onset symptom with p.Ser2Ile DES
mutation in current study; † for the first time described with p.Gly154Ser CRYAB mutation in our study; not underlined, literature findings.
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far been described: a woman harbouring the p.261-265
RAASP deletion in BAG3, who showed involvement of
the orbicularis oculi muscles and the lower limb mus-
cles, as well as photophobia and diplopia, starting at the
age of 60 years. Her muscle biopsy revealed typical
MFM findings [58].
In our patient’s nerve and muscle biopsy no giant
axons could be found, which were described before in
BAG3-associated MFM cases [36,46,48]. Muscle biopsy
findings were typical for MFM. We observed some lobu-
lated nuclei at electron microscopy, corresponding to
the findings of Selcen et al. who also described abnormal
nuclei up to apoptotic changes in one MFM patient with
a BAG3 mutation [14].
Multisystemic symptoms in MFM, unusual phenotypes
We identified new phenotypes considering the multisys-
temic symptoms of our patients in association with cer-
tain mutations in the MFM genes (Figure 2; for review
of the literature see Additional file 2). We reported
hearing impairment for the first time in patients with
the p.Arg350Pro DES mutation and for the first time in
combination with a FLNC mutation (p.Val930_Thr933del).
Also three other patients of our cohort (Table 2) pre-
sented with hearing problems, in one case (unidentified
gene defect) the complaints began at the age of 16 years.
Hearing impairment as a multisystemic symptom of
MFM was described by Kraya et al. in two patients with
a ZASP mutation, in a patient harbouring an unknownvariant in BAG3 and in one autosomal recessive DES
case, as a congenital feature [39,40,48,49].
We moreover present two new onset symptoms:
syncopes due to a conduction block associated with the
p.Ser2Ile mutation in DES and dyspnoea due to respira-
tory insufficiency for the first time with a FLNC muta-
tion. In the patient with the DES mutation mild skeletal
muscle involvement appeared only after several years.
The two reported cases with the same mutation both
showed skeletal muscle involvement at baseline [59], so
this is the first described pure cardiac onset case associ-
ated with this mutation. Moreover dysphonia was noted
in the propositus and his father. So far, only dysphagia
and nasal voice have been described with DES muta-
tions [27], dysphonia has only been described with
CRYAB mutations [31].
Respiratory insufficiency has been described in associ-
ation with the p.Trp2710X mutation in FLNC, and
frequently was the cause of death, but never the initial
symptom [11,30,60]. It was not reported as an initial
symptom in patients with other FLNC mutations, either.
Also in patient F14.1 respiratory involvement was
diagnosed, which has not been reported before with
the p.Gly154Ser mutation in CRYAB [47,61].
The high frequency of polyneuropathy in our MFM co-
hort was striking (Table 2). We found PNP in combination
with a novel BAG3 and a known MYOT (p.Ser60Phe)
mutation (Table 1). Both, BAG3 and MYOT mutations,
have been reported in MFM patients who also pre-
sented a PNP [10,14,46]. Nine additional index patients
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but no mutation was found in these cases. Thus, there
probably are other genes which cause a combined
phenotype of MFM and polyneuropathy.
The most common cardiac symptoms in our cohort
were arrhythmias (83%), followed by conduction defects
(50%). This is in accordance with a 10-year longitudinal
study in DES patients, in which conduction defects were
the most common cardiac manifestation [59].
Taking the whole cohort into account, five patients
complained about swallowing problems (one carried a
DES p.Arg350Pro mutation).
The occurrence of multisystemic symptoms might be
explained by the expression profiles of the proteins
encoded by the MFM genes. However, the expression of
proteins remains partially unknown, e.g. FLNC expres-
sion in the vestibulocochlear nerve.
Muscle MRI findings compared to the literature
For detailed values of the different muscles compared to
the literature see Table 3 [51]. Patient F1.III.1 and
patient F2.III.4 harbour the same mutation in DES
(Table 1, Figure 1). Patient F2.III.4 showed an equal
pattern of muscle involvement as described before
even after 32 years of disease duration. However, the
pattern seen in patient F1.III.1 is different, especially
his gluteus minimus, quadriceps, and soleus muscle
were far more involved than in previously reported
cases. Patient F7.III.4 carries a FLNC mutation and
showed a relatively typical pattern of muscle involve-
ment in the MRI, only the severe involvement of the
rectus femoris and semitendinosus and the spared tibi-
alis anterior muscle was rather unusual. In the patient
with a MYOT mutation (patient F10.1) we would have
expected the involvement of the tibialis anterior muscle,
because of the severely involved posterior compartment,
as well as the vastus medialis and intermedius muscles
which are described to be one of the most affected in the
literature and are only mildly involved here. In the patient
with a ZASP mutation (patient F.12.III.3) we found a
rather mild involvement at muscle MRI, but as was
described before biceps femoris and semimembranosus
muscles were most severely affected.
Conclusion
We conclude that multisystemic involvement frequently
occurs in MFM. Most important are the cardiac and re-
spiratory symptoms, but also polyneuropathies, hearing
loss and bulbar symptoms can occur. BAG3 should be
included in the genetic workup of MFM patients, even
in cases with an adult onset and a mild phenotype. In
29% of all biopsies no aggregations were found at the
light microscopic level, however, typical ultrastructural
findings were present, underlining the importance ofelectron microscopy in the diagnosis of MFM. In
contrast, 76% of the patients/biopsies without a genetic
identification showed distinct protein deposits in the
cytoplasm of the muscle cells. This high rate and our
percentage of identified mutations (37%) lead to the
conclusion that more causative genes for MFM are still
to be found. NGS might be helpful in achieving this aim.
Additional files
Additional file 1: Non-pathogenic or unclassified variants identified
by means of NGS panel diagnostics in the MFM-causing genes.
Additional file 2: Review of multisystemic symptoms described in
literature.
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